Hybrid PET/MRI in major cancers: a scoping review

Vilstrup, Mie Holm; Wallenius, Sara Elisabeth; Gerke, Oke; Petersen, Henrik; Johansen, Allan; Andersen, Troels; Høilund‐Carlsen, Poul Flemming

doi:10.1007/s00259-019-04402-8

Cited by 36 publications

(25 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the results of the present study, which showed the superiority of 18 F-FDG PET/MRI to ceCT for M staging, 18 F-FDG PET/MRI might offer a useful alternative imaging modality to ceCT, or 18 F-FDG PET/CT in the assessment of N and M staging as well as in the T staging in ovarian cancer. We could not show the superiority of 18 F-FDG PET/MRI over ceCT for N staging, although previous reports have suggested the superiority of 18 F-FDG PET/MRI compared with conventional modalities in other cancers (25). A possible reason for this lack of difference could be the small number of events and samples in our study.…”

Section: Discussioncontrasting

confidence: 77%

“…In terms of 18 F-FDG PET/MRI, no reports appear to have described the assessment of N and M staging for ovarian cancer. In other cancers, including nasopharyngeal, breast, and colorectal cancers, 18 F-FDG PET/MRI has been reported as superior compared with 18 F-FDG PET/CT for detecting lymph nodes or distant metastasis (25). Moreover, 18 F-FDG PET/MRI has been reported as equivalent to MRI in cervical cancer (22) for the detection of lymph nodes or distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Value of 18F-FDG PET/MRI For Staging in Patients With Ovarian Cancer

Tsuyoshi

Tsujikawa

Yamada

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose To evaluate the diagnostic potential of PET/MRI with 18F-fluorodeoxyglucose (18F-FDG) in ovarian cancer. Materials and Methods Participants comprised 103 patients with suspected ovarian cancer underwent pretreatment 18F-FDG PET/MRI, contrast-enhanced CT (ceCT) and pelvic dynamic contrast-enhanced MRI (ceMRI). Diagnostic performance of 18F-FDG PET/MRI and ceMRI for assessing the characterization and the extent of the primary tumor (T stage) and 18F-FDG PET/MRI and ceCT for assessing nodal (N stage) and distant (M stage) metastases was evaluated by two experienced readers. Histopathological and follow-up imaging results were used as the gold standard. The McNemar test was employed for statistical analysis. Results Accuracy for the characterization of suspected ovarian cancer was significantly better for 18F-FDG PET/MRI (92.5%) than for ceMRI (80.6%; p < 0.05). Accuracy for T status was 96.4% and 92.9% for 18F-FDG PET/MRI and ceMRI/ceCT, respectively. Patient-based accuracies for N and M status were 100% and 100% for 18F-FDG PET/MRI and 85.2% and 30.8% for ceCT and M staging representing significant differences (p < 0.01). Lesion-based sensitivity, specificity and accuracy for N status were 78.6%, 95.7% and 93.9% for 18F-FDG PET/MRI and 42.9%, 96.6% and 90.8% for ceCT. Conclusions Use of 18F-FDG PET/MRI offers higher diagnostic value for the characterization and M staging than ceMRI and ceCT, and diagnostic value for T and N staging equivalent to ceMRI and ceCT, suggesting that 18F-FDG PET/MRI might represent a useful diagnostic alternative to conventional imaging modalities in ovarian cancer.

show abstract

Section: Discussioncontrasting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of 18F-FDG PET/MRI For Staging in Patients With Ovarian Cancer

Tsuyoshi

Tsujikawa

Yamada

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Considering the results of the present study, which showed the superiority of 18 F-FDG PET/MRI to ceCT for M staging, 18 F-FDG PET/MRI might offer a useful alternative imaging modality to ceCT, or 18 F-FDG PET/CT in the assessment of N and M staging as well as in the T staging in ovarian cancer. We could not show the superiority of 18 F-FDG PET/MRI over ceCT for N staging, although previous reports have suggested the superiority of 18 F-FDG PET/MRI compared with conventional modalities in other cancers (27). A possible reason for this lack of difference could be the small number of events and samples in our study.…”

Section: Discussioncontrasting

confidence: 77%

“…In terms of 18 F-FDG PET/MRI, no reports appear to have described the assessment of N and M staging for ovarian cancer. In other cancers, including nasopharyngeal, breast, and colorectal cancers, 18 F-FDG PET/MRI has been reported as superior compared with 18 F-FDG PET/CT for detecting lymph nodes or distant metastasis (27). Moreover, 18 F-FDG PET/MRI has been reported as equivalent to MRI in cervical cancer (24) for the detection of lymph nodes or distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of 18F-FDG PET/MRI for staging in patients with ovarian cancer

Tsuyoshi

Tsujikawa

Yamada

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: To evaluate the diagnostic potential of PET/MRI with 18F-fluorodeoxyglucose (18F-FDG) in ovarian cancer.Materials and Methods: Participants comprised 103 patients with suspected ovarian cancer underwent pretreatment 18F-FDG PET/MRI, contrast-enhanced CT (ceCT) and pelvic dynamic contrast-enhanced MRI (ceMRI). Diagnostic performance of 18F-FDG PET/MRI and ceMRI for assessing the characterization and the extent of the primary tumor (T stage) and 18F-FDG PET/MRI and ceCT for assessing nodal (N stage) and distant (M stage) metastases was evaluated by two experienced readers. Histopathological and follow-up imaging results were used as the gold standard. The McNemar test was employed for statistical analysis.Results: Accuracy for the characterization of suspected ovarian cancer was significantly better for 18F-FDG PET/MRI (92.5%) [95% confidence interval (CI) 0.841–0.950] than for ceMRI (80.6%) (95%CI 0.715–0.830) (p <0.05). Accuracy for T status was 96.4% (95%CI 0.964–0.964) and 92.9% (95%CI 0.929–0.929) for 18F-FDG PET/MRI and ceMRI/ceCT, respectively. Patient-based accuracies for N and M status were 100% (95%CI 0.883–1.000) and 100% (95%CI 0.884–1.000) for 18F-FDG PET/MRI and 85.2% (95%CI 0.758–0.852) and 30.8% (95%CI 0.188–0.308) for ceCT and M staging representing significant differences (p<0.01). Lesion-based sensitivity, specificity and accuracy for N status were 78.6% (95%CI 0.571–0.913), 95.7% (95%CI 0.932–0.972) and 93.9% (95%CI 0.893–0.966) for 18F-FDG PET/MRI and 42.9% (95%CI 0.240–0.581), 96.6% (95%CI 0.943–0.984) and 90.8% (95%CI 0.868–0.941) for ceCT. Conclusions: Use of 18F-FDG PET/MRI offers better sensitivity and specificity for the characterization and M staging than ceMRI and ceCT, and diagnostic value for T and N staging equivalent to ceMRI and ceCT, suggesting that 18F-FDG PET/MRI might represent a useful diagnostic alternative to conventional imaging modalities in ovarian cancer.

show abstract

“…These studies demonstrated a high predictive value of post therapy FDG uptake [8]. Radiotherapy planning studies using [ 18 F]-FDG-PET/CT or [ 18 F]-FDG-PET/MRI resulted in an improved detection of the gross tumour volume (GTV) in comparison with structural imaging (either CT or MRI) alone [9][10][11]. On the other hand, the limitations of [ 18 F]-FDG-PET have to be considered when it comes to the specificity of the uptake since several structures in the neck show physiological or inflammation-related uptake of glucose influencing the correct contouring of the tumour significantly [9].…”

mentioning

confidence: 99%